Donor-specific anti-HLA antibodies by solid phase immunoassays: advantages and technical concerns

References

• Hodges AM, Lyster H, McDermott A. Late antibody-mediated rejection after heart transplantation following the development of de novo donor-specific human leukocyte antigen antibody. Transplantation 2012;93(6):650–656.
   PubMed Web of Science ®Google Scholar
• Tran A, Fixler D, Huang R, et al. Donor-specific HLA alloantibodies: impact on cardiac allograft vasculopathy, rejection, and survival after pediatric heart transplantation. J Heart Lung Transplant 2016;35(1):87–91.
   PubMed Web of Science ®Google Scholar
• Kamburova EG, Wisse BW, Joosten I, et al. Differential effects of donor-specific HLA antibodies in living-versus deceased-donor transplantation. Am J Transplant 2018;18(9):2274–2284.
   PubMedGoogle Scholar
• Clemmensen TS, Koefoed-Nielsen P, Jensen LA, et al. Donor-specific antibodies are associated with micro- and macrovascular coronary disease, restrictive myocardial damage, and poor outcome in heart-transplanted patients. Clin Transplant 2017;31(9). doi: 10.1111/ctr.13033
   PubMed Web of Science ®Google Scholar
• Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol. 2010;21(8):1398–1406.
   PubMed Web of Science ®Google Scholar
• Jackson AM. The virtual crossmatch: an essential tool for transplanting sensitized patients. Clin Transpl 2014;131–136.
   PubMedGoogle Scholar
• Shrestha S, Bradbury L, Boal M, et al. Logistical factors influencing cold ischemia times in deceased donor kidney transplants. Transplantation 2016;100(2):422–428.
   PubMed Web of Science ®Google Scholar
• Eby BC, Redfield RR, Ellis TM, et al. Virtual HLA crossmatching as a means to safely expedite transplantation of imported pancreata. Transplantation 2016;100(5):1103–1110.
   PubMed Web of Science ®Google Scholar
• Heidt S, Witvliet MD, Haasnoot GW, Claas FH. The 25th anniversary of the Eurotransplant acceptable mismatch program for highly sensitized patients. Transpl Immunol 2015;33(2):51–57.
   PubMed Web of Science ®Google Scholar
• Koefoed-Nielsen P, Weinreich I, Bengtsson M, et al. Scandiatransplant acceptable mismatch program (STAMP): a bridge to transplanting highly immunized patients. HLA 2017;90(1):17–24.
   PubMed Web of Science ®Google Scholar
• Heidt S, Haasnoot GW, van Rood JJ, et al. Kidney allocation based on proven acceptable antigens results in superior graft survival in highly sensitized patients. Kidney Int 2018;93(2):491–500.
   PubMed Web of Science ®Google Scholar
• Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol 2014;5:520
   PubMed Web of Science ®Google Scholar
• Lefaucheur C, Viglietti D, Bentlejewski C, et al. IgG donor-specific anti-human HLA antibody subclasses and kidney allograft antibody-mediated injury. J Am Soc Nephrol 2016;27(1):293–304.
   PubMed Web of Science ®Google Scholar
• Collins AM, Jackson KJ. A temporal model of human IgE and IgG antibody function. Front Immunol 2013;4:235
   PubMed Web of Science ®Google Scholar
• Arnold ML, Bach C, Heinemann FM, et al. Anti-HLA alloantibodies of the IgA isotype in re-transplant candidates part II: correlation with graft survival. Int J Immunogenet 2018;45(3):95–101.
   PubMed Web of Science ®Google Scholar
• Lowe D, Higgins R, Zehnder D, Briggs DC. Significant IgG subclass heterogeneity in HLA-specific antibodies: Implications for pathogenicity, prognosis, and the rejection response. Hum Immunol 2013;74(5):666–672.
   PubMed Web of Science ®Google Scholar
• Taylor CJ, Kosmoliaptsis V, Martin J, et al. Technical limitations of the C1q single-antigen bead assay to detect complement binding HLA-specific antibodies. Transplantation 2017;101(6):1206–1214.
   PubMed Web of Science ®Google Scholar
• Schaub S, Honger G, Koller MT, et al. Determinants of C1q binding in the single antigen bead assay. Transplantation 2014;98(4):387–393.
   PubMed Web of Science ®Google Scholar
• Viglietti D, Loupy A, Vernerey D, et al. Value of donor-specific anti-HLA antibody monitoring and characterization for risk stratification of kidney allograft loss. JASN 2017;28(2):702–715.
   Web of Science ®Google Scholar
• Yamamoto T, Watarai Y, Takeda A, et al. De Novo anti-HLA DSA characteristics and subclinical antibody-mediated kidney allograft injury. Transplantation 2016;100(10):2194–2202.
   PubMed Web of Science ®Google Scholar
• Fichtner A, Susal C, Hocker B, et al. Association of C1q-fixing DSA with late graft failure in pediatric renal transplant recipients. Pediatr Nephrol 2016;31(7):1157–1166.
   PubMed Web of Science ®Google Scholar
• Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 2013;369(13):1215–1226.
   PubMed Web of Science ®Google Scholar
• Sutherland SM, Chen G, Sequeira FA, et al. Complement-fixing donor-specific antibodies identified by a novel C1q assay are associated with allograft loss. Pediatr Transplant 2012;16(1):12–17.
   PubMed Web of Science ®Google Scholar
• Freitas MC, Rebellato LM, Ozawa M, et al. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes. Transplantation 2013;95(9):1113–1119.
   PubMed Web of Science ®Google Scholar
• Oi VT, Vuong TM, Hardy R, et al. Correlation between segmental flexibility and effector function of antibodies. Nature 1984;307(5947):136–140.
   PubMed Web of Science ®Google Scholar
• Garred P, Michaelsen TE, Aase A. The IgG subclass pattern of complement activation depends on epitope density and antibody and complement concentration. Scand J Immunol 1989;30(3):379–382.
   PubMed Web of Science ®Google Scholar
• Duquesnoy RJ, Marrari M, Jelenik L, et al. Structural aspects of HLA class I epitopes reacting with human monoclonal antibodies in Ig-binding, C1q-binding and lymphocytotoxicity assays. Hum Immunol 2013;74(10):1271–1279.
   PubMed Web of Science ®Google Scholar
• Yang D, Kroe-Barrett R, Singh S, et al. IgG cooperativity - Is there allostery? Implications for antibody functions and therapeutic antibody development. MAbs 2017;9(8):1231–1252.
   PubMed Web of Science ®Google Scholar
• Honger G, Amico P, Arnold ML, et al. Effects of weak/non-complement-binding HLA antibodies on C1q-binding. HLA 2017;90(2):88–94.
   PubMed Web of Science ®Google Scholar
• Valenzuela NM, Schaub S. The biology of IgG subclasses and their clinical relevance to transplantation. Transplantation 2018;102(1S Suppl 1):S7–S13.
   PubMedGoogle Scholar
• Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 2012;119(24):5640–5649.
   PubMed Web of Science ®Google Scholar
• Valenzuela NM, Trinh KR, Mulder A, et al. Monocyte recruitment by HLA IgG-activated endothelium: the relationship between IgG subclass and FcgammaRIIa polymorphisms. Am J Transplant. 2015;15(6):1502–1518.
   PubMed Web of Science ®Google Scholar
• Arnold ML, Kainz A, Hidalgo LG, et al. Functional Fc gamma receptor gene polymorphisms and donor-specific antibody-triggered microcirculation inflammation. Am J Transplant 2018;18(9):2261–2273.
   Web of Science ®Google Scholar
• Katerinis I, Hadaya K, Duquesnoy R, et al. De novo anti-HLA antibody after pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients. Am J Transplant 2011;11(8):1727–1733.
   PubMed Web of Science ®Google Scholar
• Fischer AS, Moller BK, Krag S, Jespersen B. Influenza virus vaccination and kidney graft rejection: causality or coincidence. Clin Kidney J 2015;8(3):325–328.
   PubMed Web of Science ®Google Scholar
• Jindra PT, Zhang X, Mulder A, et al. Anti-HLA antibodies can induce endothelial cell survival or proliferation depending on their concentration. Transplantation 2006;82(Supplement 1):S33–S35.
   PubMed Web of Science ®Google Scholar
• Jin YP, Valenzuela NM, Zhang X, et al. HLA Class II-triggered signaling cascades cause endothelial cell proliferation and migration: relevance to antibody-mediated transplant rejection. JI 2018;200(7):2372–2390.
   Google Scholar
• Desy O, Beland S, Vallin P, et al. Allogeneic dendritic cells stimulated with antibodies against HLA class II polarize naive T cells in a follicular helper phenotype. Sci Rep 2018;8(1):4025.
   PubMedGoogle Scholar
• Baker K, Rath T, Pyzik M, Blumberg RS. The role of FcRn in antigen presentation. Front Immunol 2014;5:408.
   PubMed Web of Science ®Google Scholar
• Perasaari JP, Jaatinen T, Merenmies J. Donor-specific HLA antibodies in predicting crossmatch outcome: comparison of three different laboratory techniques. Transpl Immunol 2018;46:23–28.
   PubMed Web of Science ®Google Scholar
• Tambur AR, Wiebe C. HLA diagnostics: evaluating DSA strength by titration. Transplantation 2018;102(1S Suppl 1):S23–S30.
   PubMedGoogle Scholar
• Caro-Oleas JL, Gonzalez-Escribano MF, Gentil-Govantes MA, et al. Influence of donor specific HLA antibodies detected by Luminex in kidney graft survival: a multivariate analysis. Hum Immunol 2013;74(5):545–549.
   PubMed Web of Science ®Google Scholar
• Sullivan HC, Gebel HM, Bray RA. Understanding solid-phase HLA antibody assays and the value of MFI. Hum Immunol 2017;78(7–8):471–480.
   PubMed Web of Science ®Google Scholar
• McCutcheon JA, Gumperz J, Smith KD, et al. Low HLA-C expression at cell surfaces correlates with increased turnover of heavy chain mRNA. J Exp Med 1995;181(6):2085–2095.
   PubMed Web of Science ®Google Scholar
• Schnaidt M, Weinstock C, Jurisic M, et al. HLA antibody specification using single-antigen beads–a technical solution for the prozone effect. Transplantation 2011;92(5):510–515.
   PubMed Web of Science ®Google Scholar
• Visentin J, Guidicelli G, Bachelet T, et al. Denatured class I human leukocyte antigen antibodies in sensitized kidney recipients: prevalence, relevance, and impact on organ allocation. Transplantation 2014;98(7):738–744.
   PubMed Web of Science ®Google Scholar
• Schwaiger E, Wahrmann M, Bond G, et al. Complement component C3 activation: the leading cause of the prozone phenomenon affecting HLA antibody detection on single-antigen beads. Transplantation 2014;97(12):1279–1285.
   PubMed Web of Science ®Google Scholar
• Weinstock C, Schnaidt M. The complement-mediated prozone effect in the Luminex single-antigen bead assay and its impact on HLA antibody determination in patient sera. Int J Immunogenet 2013;40(3):171–177.
   PubMed Web of Science ®Google Scholar
• Wang J, Meade JR, Brown NK, et al. EDTA is superior to DTT treatment for overcoming the prozone effect in HLA antibody testing. HLA 2017;89(2):82–89.
   PubMed Web of Science ®Google Scholar
• Guidicelli G, Visentin J, Franchini N, et al. Prevalence, distribution and amplitude of the complement interference phenomenon in single antigen flow beads assays. HLA 2018;91(6):507–513.
   PubMed Web of Science ®Google Scholar
• Sullivan HC, Liwski RS, Bray RA, Gebel HM. The road to HLA antibody evaluation: do not rely on MFI. Am J Transplant 2017;17(6):1455–1461.
   PubMed Web of Science ®Google Scholar
• El-Awar N, Terasaki PI, Nguyen A, et al. Epitopes of HLA antibodies found in sera of normal healthy males and cord blood. Clin Transpl 2008;199–214.
   PubMedGoogle Scholar
• Morales-Buenrostro LE, Terasaki PI, Marino-Vázquez LA, et al. Natural human leukocyte antigen antibodies found in nonalloimmunized healthy males. Transplantation 2008;86(8):1111–1115.
   PubMed Web of Science ®Google Scholar
• Jacob EK, De Goey SR, Gandhi MJ. Positive virtual crossmatch with negative flow crossmatch results in two cases. Transpl Immunol 2011;25(1):77–81.
   PubMed Web of Science ®Google Scholar
• Pereira S, Perkins S, Lee J-H, et al. Donor-specific antibody against denatured HLA-A1: clinically nonsignificant?. Hum Immunol 2011;72(6):492–498.
   PubMed Web of Science ®Google Scholar
• Gombos P, Opelz G, Scherer S, et al. Influence of test technique on sensitization status of patients on the kidney transplant waiting list. Am J Transplant 2013;13(8):2075–2082.
   PubMed Web of Science ®Google Scholar
• Otten HG, Verhaar MC, Borst HP, et al. The significance of pretransplant donor-specific antibodies reactive with intact or denatured human leucocyte antigen in kidney transplantation. Clin Exp Immunol 2013;173(3):536–543.
   PubMed Web of Science ®Google Scholar
• Visentin J, Marroc M, Guidicelli G, et al. Clinical impact of preformed donor-specific denatured class I HLA antibodies after kidney transplantation. Clin Transplant 2015;29(5):393–402.
   PubMed Web of Science ®Google Scholar
• Konvalinka A, Tinckam K. Utility of HLA antibody testing in kidney transplantation. J Am Soc Nephrol 2015;26(7):1489–1502.
   PubMed Web of Science ®Google Scholar
• Tait BD, Susal C, Gebel HM, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013;95(1):19–47.
   PubMed Web of Science ®Google Scholar
• Pena JR, Fitzpatrick D, Saidman SL. Complement-dependent cytotoxicity crossmatch. In: Zachary AA, Leffell MS, editors. Transplantation immunology: methods and protocols, methods in molecular biology. Vol. 1034. 2nd ed. Springer Nature Switzerland AG; 2013, pp. 257–283.
   Google Scholar
• Koefoed-Nielsen P, Bistrup C, Christiansen M. Protein a immunoadsorption May Hamper the decision to transplant due to interference with CDC crossmatch results. J Clin Apher 2017;32(3):163–169.
   PubMed Web of Science ®Google Scholar
• El-Awar N, Jucaud V, Nguyen A. HLA epitopes: the targets of monoclonal and alloantibodies defined. J Immunol Res 2017;2017:3406230
   PubMedGoogle Scholar
• Duquesnoy RJ, Askar M. HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. V. Eplet matching for HLA-DR, HLA-DQ, and HLA-DP. Hum Immunol 2007;68(1):12–25.
   PubMed Web of Science ®Google Scholar
• Duquesnoy RJ. Are we ready for epitope-based HLA matching in clinical organ transplantation? Transplantation 2017;101(8):1755–1765.
   PubMed Web of Science ®Google Scholar
• Kosmoliaptsis V, Mallon DH, Chen Y, et al. Alloantibody responses after renal transplant failure can be better predicted by donor-recipient HLA amino acid sequence and physicochemical disparities than conventional HLA matching. Am J Transplant 2016;16(7):2139–2147.
   PubMed Web of Science ®Google Scholar
• Mallon DH, Bradley JA, Winn PJ, et al. Three-dimensional structural modelling and calculation of electrostatic potentials of HLA Bw4 and Bw6 epitopes to explain the molecular basis for alloantibody binding: toward predicting HLA antigenicity and immunogenicity. Transplantation 2015;99(2):385–390.
   PubMed Web of Science ®Google Scholar
• Tambur AR, Rosati J, Roitberg S, et al. Epitope analysis of HLA-DQ antigens: what does the antibody see?. Transplantation 2014;98(2):157–166.
   PubMed Web of Science ®Google Scholar
• Mikkelsen S, Korsholm T, Iburg A, et al. Case report: binding of a clinically relevant human leukocyte antigen-DQalpha-specific antibody in a kidney graft recipient is inhibited by donor-type human leukocyte antigen-DQbeta chain. Transplant Proc 2013;45(3):1209–1212.
   PubMed Web of Science ®Google Scholar
• Tambur AR, Campbell P, Claas FH, et al. Sensitization in Transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report. Am J Transplant 2018;18(7):1604–1614.
   Web of Science ®Google Scholar